Subtopic Deep Dive
Chemotherapy-Induced Peripheral Neuropathy
Research Guide
What is Chemotherapy-Induced Peripheral Neuropathy?
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a dose-limiting sensory neuropathy caused by antineoplastic agents like taxanes and platinums, affecting up to 60% of cancer patients.
CIPN manifests as pain, numbness, and tingling, often leading to chemotherapy dose reduction or cessation (Seretny et al., 2014, 1449 citations). Incidence varies from 19-85% depending on agent and cumulative dose (Zajączkowska et al., 2019, 755 citations). Over 30 meta-analyses and guidelines address its mechanisms, prevention, and management.
Why It Matters
CIPN impacts quality of life for 30-40% of patients on neurotoxic chemotherapy, causing persistent symptoms post-treatment (Staff et al., 2017, 811 citations). It limits treatment efficacy by necessitating dose reductions, as seen in taxane and platinum regimens (Hershman et al., 2014, 1196 citations). ASCO guidelines highlight unmet needs in prevention, with duloxetine as the only recommended agent (Loprinzi et al., 2020, 947 citations), driving research into biomarkers and neuroprotective strategies.
Key Research Challenges
Lack of Prevention Strategies
No effective pharmacological prevention exists despite high incidence (Seretny et al., 2014, 1449 citations). Trials show inconsistent cryotherapy and exercise benefits (Hershman et al., 2014). ASCO updates confirm limited evidence for most interventions (Loprinzi et al., 2020).
Heterogeneous Patient Risk Factors
Predictors like cumulative dose and genetics vary across agents (Seretny et al., 2014). Taxanes cause acute symptoms while platinums lead to chronic deficits (Quasthoff and Hartung, 2002, 959 citations). Meta-analyses reveal inconsistent reporting of outcomes (Park et al., 2013).
Inadequate Assessment Tools
Patient-reported outcomes often mismatch clinical exams (Postma et al., 2005, 551 citations). QLQ-CIPN20 validates sensory symptoms but lacks motor specificity (Staff et al., 2017). Guidelines call for standardized grading (Hershman et al., 2014).
Essential Papers
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
Marta Seretny, Gillian L. Currie, Emily S. Sena et al. · 2014 · Pain · 1.4K citations
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting from chemotherapy for cancer. Severe acute CIPN may require chemotherapy dose reduction or cessation. There...
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman, Christina Lacchetti, Robert H. Dworkin et al. · 2014 · Journal of Clinical Oncology · 1.2K citations
Purpose To provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. Met...
Chemotherapy-induced peripheral neuropathy
Stefan Quasthoff, Hans Hartung · 2002 · Journal of Neurology · 959 citations
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
Charles L. Loprinzi, Christina Lacchetti, Jonathan Bleeker et al. · 2020 · Journal of Clinical Oncology · 947 citations
PURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS...
Chemotherapy‐induced peripheral neuropathy: A current review
Nathan P. Staff, Anna Grisold, Wolfgang Grisold et al. · 2017 · Annals of Neurology · 811 citations
Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neur...
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Renata Zajączkowska, Magdalena Kocot-Kępska, Wojciech Leppert et al. · 2019 · International Journal of Molecular Sciences · 755 citations
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sens...
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Susanna B. Park, David Goldstein, Arun V. Krishnan et al. · 2013 · CA A Cancer Journal for Clinicians · 722 citations
With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long‐term t...
Reading Guide
Foundational Papers
Start with Seretny et al. (2014, 1449 citations) for incidence meta-analysis; Quasthoff and Hartung (2002, 959 citations) for mechanisms; Hershman et al. (2014, 1196 citations) for initial ASCO guidelines.
Recent Advances
Loprinzi et al. (2020, 947 citations) ASCO update on duloxetine; Zajączkowska et al. (2019, 755 citations) on molecular mechanisms; Staff et al. (2017, 811 citations) on prevalence.
Core Methods
Meta-analysis for incidence (Seretny et al., 2014); QLQ-CIPN20 for outcomes (Postma et al., 2005); GRADE evidence grading in guidelines (Hershman et al., 2014).
How PapersFlow Helps You Research Chemotherapy-Induced Peripheral Neuropathy
Discover & Search
Research Agent uses searchPapers and citationGraph on Seretny et al. (2014) to map 1449 citing papers, revealing clusters on taxane vs. platinum CIPN. exaSearch queries 'CIPN biomarkers taxanes' to surface 755-citation Zajączkowska et al. (2019). findSimilarPapers expands from Hershman et al. (2014) ASCO guideline to 50+ prevention trials.
Analyze & Verify
Analysis Agent applies readPaperContent to extract incidence rates from Seretny et al. (2014), then runPythonAnalysis with pandas to meta-analyze prevalence across 12 studies (30-60% range). verifyResponse (CoVe) checks claims against Loprinzi et al. (2020) update, with GRADE grading assigning moderate evidence to duloxetine. Statistical verification confirms risk ratios via NumPy sandbox.
Synthesize & Write
Synthesis Agent detects gaps in prevention trials post-2020 using contradiction flagging on ASCO guidelines. Writing Agent employs latexEditText for CIPN review sections, latexSyncCitations to integrate Seretny et al. (2014), and latexCompile for publication-ready manuscript. exportMermaid visualizes mechanistic pathways from Starobova and Vetter (2017).
Use Cases
"Analyze CIPN incidence meta-data from Seretny 2014 with statistics."
Research Agent → searchPapers('Seretny CIPN') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas meta-analysis of 30-85% prevalence) → matplotlib plot of taxane/platinum risks.
"Write LaTeX review on CIPN prevention guidelines."
Synthesis Agent → gap detection (Hershman 2014 vs. Loprinzi 2020) → Writing Agent → latexEditText (structure sections) → latexSyncCitations (1196+947 refs) → latexCompile (PDF with tables).
"Find code for CIPN patient-reported outcome models."
Research Agent → paperExtractUrls (Postma QLQ-CIPN20 2005) → paperFindGithubRepo → githubRepoInspect (R scripts for neuropathy scoring) → exportCsv (symptom severity datasets).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ CIPN papers) → citationGraph → GRADE grading → structured ASCO-aligned report on prevention gaps. DeepScan applies 7-step analysis to Quasthoff (2002): readPaperContent → verifyResponse → runPythonAnalysis on mechanisms. Theorizer generates hypotheses on genetic predictors from Seretny et al. (2014) predictors.
Frequently Asked Questions
What is Chemotherapy-Induced Peripheral Neuropathy?
CIPN is a sensory-dominant neuropathy from chemotherapy agents like taxanes and platinums, with 19-85% prevalence (Zajączkowska et al., 2019).
What are main assessment methods for CIPN?
QLQ-CIPN20 questionnaire measures patient-reported sensory symptoms (Postma et al., 2005, 551 citations). Clinical grading uses NCI-CTCAE scales per ASCO guidelines (Hershman et al., 2014).
What are key papers on CIPN?
Seretny et al. (2014, 1449 citations) meta-analysis on incidence; Hershman et al. (2014, 1196 citations) and Loprinzi et al. (2020, 947 citations) ASCO guidelines on management.
What are open problems in CIPN research?
Effective prevention lacks; only duloxetine recommended (Loprinzi et al., 2020). Biomarkers for risk prediction and long-term motor deficits remain undeveloped (Staff et al., 2017).
Research Cancer Treatment and Pharmacology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chemotherapy-Induced Peripheral Neuropathy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Treatment and Pharmacology Research Guide